Jorge Conde knows what CAR-T cancer therapy is.

Conde is a biotech partner at the Silicon Valley venture capital firm Andreessen Horowitz, meaning he makes his living investing in new medicines. Why it’s worth pointing out that he has heard of perhaps the biggest advance in oncology in recent years is, well, a long and extremely online story.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I think the issue here is not necessarily just Conde’s credentials but how he is hyping a technology that was “new” in 2013, as if it just got discovered. It’s a form of appropriation – taking the innovation someone else has done (and like more than half a decade ago) and claiming as if you are involved in or responsible for it somehow. Conde is not funding the pioneering work of CAR-T, but rather the follow-on work (still important, for sure), and yet his Tweet suggests he’s doing the former, instead of the latter.

    This just makes me think Conde is a poser, like many Silicon Valley VCs are. You have to look no further than the Silicon Valley VCs who funded Theranos.

Your daily dose of news in health and medicine

Privacy Policy